213 related articles for article (PubMed ID: 34477165)
1. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
[TBL] [Abstract][Full Text] [Related]
2. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.
Deng W; Chen J; Deng XY
Front Immunol; 2024; 15():1333850. PubMed ID: 38487532
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review.
Jiang Y; Zhang L; Zhu F; Zhu H; Cao X; Zhang Y
Ann Palliat Med; 2022 Mar; 11(3):1135-1146. PubMed ID: 35365044
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
7. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract][Full Text] [Related]
8. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
Yu G; Cai Q; Xu X; Shen Y; Xu K
PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.
Wu Y; Zhang T; Liu Y; Wang J; Bi N
Ann Palliat Med; 2021 Feb; 10(2):2379-2386. PubMed ID: 33725780
[TBL] [Abstract][Full Text] [Related]
11. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
Su H; Yu C; Ma X; Song Q
Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib in treatment of an elderly patient with recurrent advanced SCLC.
Zhang Y; Jia B; Li J; Xu X
Tumori; 2020 Dec; 106(6):NP36-NP40. PubMed ID: 32031060
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
15. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
16. Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
Wu G; Huang J; Lin L; Yan S; Pan W; Chen Q; Wu X; Lv D
Immunotherapy; 2022 Sep; 14(13):1007-1013. PubMed ID: 35852100
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Liu C; Liao J; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Wang J
Thorac Cancer; 2022 May; 13(10):1463-1470. PubMed ID: 35388976
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.
Gao F; Cong X; Liu Z
Medicine (Baltimore); 2020 Oct; 99(40):e22637. PubMed ID: 33019486
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
Wang N; Zhao L; Zhang D; Kong F
Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
